Drug Profile

OK 201

Alternative Names: BAM-8; BAM8-22; OK-201; OKYO-0201

Latest Information Update: 02 Jan 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Tufts University
Developer OKYO Pharma
Class Eye disorder therapies; Lipids; Non-opioid analgesics; Peptides
Mechanism of Action G protein-coupled receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Neuropathic pain; Ocular pain

Most Recent Events

26 Jan 2022 Discontinued - Preclinical for Neuropathic pain in United Kingdom
26 Jan 2022 Discontinued - Preclinical for Ocular pain in United Kingdom (Ophthalmic)
26 Jan 2021 OKYO Pharma has patent protection for bovine adrenal medulla (BAM) peptides in USA

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com